ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Epidemiology"

  • Abstract Number: 2685 • ACR Convergence 2025

    Assessing for Racial/Ethnic Variability in U.S.-FRAXTM Performance Among Older Adult Women with Rheumatoid Arthritis in the United States

    Rachel Elam1, Jing Li2, Angel Paul3, Emma Kersey4, gabriela Schmajuk5, William Leslie6 and Laura Carbone1, 1Augusta University, Augusta, GA, 2University of California, San Francisco, San Francisco, CA, 3University of California San Francisco, Berkeley, CA, 4University of California San Francisco, San Francisco, CA, 5University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, 6University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Women with rheumatoid arthritis (RA) have 1.5- and 2-fold higher risk of major osteoporotic fracture (MOF: first of distal forearm, hip, humerus, or clinical…
  • Abstract Number: 2336 • ACR Convergence 2025

    Early Axial Spondyloarthritis in Latin America: Prevalence and Regional Differences from the “ESPALDA” Multinational Registry

    Wilson bautista molano1, Guillermo Guaracha2, Fernando Sommerfleck3, Rodrigo García Salinas4, Julio Cesar Casasola Vargas5, John Londono6, Daniel Fernandez7, Diego Vila8, Lorena Brance9, Jossiel Then10, francisco Zeballos11, Lysseth Macias12, Marilu mestanza13, Daisy Sanchez14, lYN chincháy15, Patricia Melgarejo16, Angel Castillo17, Gimena Gomez18, Leandro ferreryra19, Dora candia20, Gustavo medina21, Maria Erguez22, Einer Sanchez4 and Daniel Palleiro23, 1University Hospital Fundacion Santa Fe de Bogota, Bogota, Colombia, 2Instituto Nacional de Ciencias Médicas y Nutrición 'Salvador Zubirán', Ciudad de México, Mexico, Mexico, 3Sanatorio Julio Mendez, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 4Hospital Italiano La Plata, La Plata, Argentina, 5CAVJ7111038Q9, MEXICO CITY, Mexico, 6Hospital Militar Central , Universidad de La Sabana, Colombia, Bogota, Colombia, 7Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia; Departamento de Medicina Interna, Unidad de Reumatología, Hospital Universitario San Ignacio, Bogotá, Colombia, BOGOTA, Colombia, 8Hospital Virgen del Carmen, Buenos Aires, Argentina, Buenos Aires, Argentina, 9School of Medicine, Rosario National University, Argentina, Rosario, Argentina, 10HOMS, Santiago, Dominican Republic, 11Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, 12Consultorio sse, Hospital Metropolitano, Ecuador, Quito, Ecuador, 13Hospital Metropolitano, Ecuador, Quito, Ecuador, 14Sociedad Ecuatoriana de Reumatología, GUAYAS - GUAYAQUIL, Ecuador, 15Hospital Guillermo Kaelin de La Fuente, Perú, Lima, Peru, 16Instituto de Previsión Social, Villarrica, Paraguay, 17Centro médico de las Americas, Merida, Mexico, 18Sanatorio Guemes, Buenos Aires, Argentina, 19HIBA, CABA, Ciudad Autonoma de Buenos Aires, Argentina, 20Hospital Regional Primero de Octubre ISSTE, Fuerzas Armadas, México, Durango, Mexico, 21Clinical Hospital Buenos Aires University, Quilmes, Argentina, 22SAR, Guayaquil, Ecuador, 23INRU, Montevideo, Uruguay

    Background/Purpose: The ESPALDA registry, developed by PANLAR, collects data from Latin America to better understand the clinical and epidemiological characteristics of patients with axial spondyloarthritis…
  • Abstract Number: 1911 • ACR Convergence 2025

    Characterizing Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Insights from the STOP PsA At-Risk Cohort

    Victoria Konzett1, Eva Manger2, Simon Reider2, Johannes Griss3, Constanze Jonak3, Kastriot Kastrati4, Peter Mandl4, Gudrun Ratzinger5, Christina Duftner2, Thomas Karonitsch4 and Daniel Aletaha6, 1Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria, 3Department of Dermatology, Medical University of Vienna, Austria, Vienna, Austria, 4Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 5Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Austria, Innsbruck, Austria, 6Medical University Vienna, Wien, Austria

    Background/Purpose: Psoriatic arthritis (PsA) develops predominantly in patients with psoriasis (Pso). Although key drivers and predictors of disease progression have been identified in recent years,…
  • Abstract Number: 1886 • ACR Convergence 2025

    Thirty Percent of Older Adults with Rheumatic Disease Receive High-Risk Medication

    Christine Anastasiou1, Eric Roberts2, gabriela Schmajuk3 and Jinoos Yazdany4, 1Stanford University, Pleasanton, CA, 2University of California, San Francisco, SF, CA, 3University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, 4UCSF, San Francisco, CA

    Background/Purpose: High-risk medications (HRMs) may increase the risk of adverse events such as falls and fractures, hospitalizations, hospital length of stay, and death in older…
  • Abstract Number: 1583 • ACR Convergence 2025

    Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021

    Patompong Ungprasert1 and Paul Kroner2, 1Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH, 2Riverside Health System, Newport News, VA

    Background/Purpose: The inpatient epidemiology, morbidity, mortality, and healthcare expenditures of patients with systemic sclerosis (SSc) are not well-characterized. This study aims to utilize a nationwide…
  • Abstract Number: 1279 • ACR Convergence 2025

    Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.

    Reagan Reid1, Huayun Hou2, Isha Datar2, Daniela Dominguez3, Andrea Knight4, Deborah Levy5, Lawrence Ng6, Zhaoyu Ding2, Michael Wilson2, Lauren Erdman7, Eleanor Pullenayegum2 and Linda Hiraki5, 1The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 2SickKids Research Institute, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, Canada, 4Hospital for Sick Children, Toronto, ON, Canada, 5The Hospital for Sick Children, Toronto, ON, Canada, 6The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, 7University of Cincinnati, Cincinnati, OH

    Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a clinically and genetically heterogeneous disease. We aimed to define subgroups of new diagnosis patients based on treatment…
  • Abstract Number: 1016 • ACR Convergence 2025

    Association between inflammatory biomarkers and predicted heart failure risk in rheumatoid arthritis

    Ilana Usiskin1, Lauren rusnak2, Katherine Zhong3, Ying Qi4, Nicole Yang2, Gregory McDermott5, Brittany Weber6 and Katherine Liao2, 1Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Short Hills, NJ, 4Brigham and Women’s Hospital, Boston, 5Brigham and Women's Hospital, Brookline, MA, 6Brigham and Women's Hospital, DEDHAM, MA

    Background/Purpose: Heart failure (HF) is a major cause of morbidity and mortality in rheumatoid arthritis (RA). Prior work has suggested that higher levels of inflammation…
  • Abstract Number: 0734 • ACR Convergence 2025

    Glucocorticoid Exposure and Comorbidity Profile in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: a multi-country cohort study

    Julie Mouchet1, Lauren Revie2, Tim Nguyen3, Liwei Zhao4, Valeria Jordan M.5, G S Ramakrishna6, Linda Grinnell-Merrick3, Atif Adam7 and Minouk Schoemaker8, 1Novartis Pharma AG, Basel, Switzerland, 2IQVIA, EMEA, London, United Kingdom, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4IQVIA, Real World Solutions, Mölndal, Sweden, 5Novartis Pharmaceuticals Corporation, Tenafly, NJ, 6Novartis Healthcare Private Limited, Hyderabad, India, 7IQVIA Inc, Boston, 8IQVIA, Real World Solutions, Amsterdam, Netherlands

    Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory conditions that predominantly affect individuals ≥50 years of age. The conditions share overlapping…
  • Abstract Number: 0321 • ACR Convergence 2025

    Per- and Polyfluoroalkyl Substances and Hand Osteoarthritis: Data from the Osteoarthritis Initiative

    Jeffrey Driban1, Lisa Rokoff2, Bing Lu3, Timothy McAlington4, Charles Eaton5, Mary Roberts6, Diana Mathes7, Colleen Lestician7, Zhijin Carrie Xu7, Zhihua Tina Fan7, Shawn O'Leary7 and Abby Fleisch8, 1University of Massachusetts Chan Medical School, Marlborough, NH, 2Center for Interdisciplinary and Population Health Research, MaineHealth Institute for Research, Westbrook, ME, 3UConn Health Center, Newton, MA, 4UMass Chan School of Medicine, Arlington, MA, 5Brown University, Pawtucket, RI, 6Center for Primary Care and Prevention, Kent Hospital, Pawtucket, RI, 7Environmental and Chemical Laboratory Services, Public Health & Environmental Laboratories, New Jersey Department of Health, Ewing, NJ, 8Maine Medical Center; 2. Center for Interdisciplinary and Population Health Research, MaineHealth Institute for Research, Westbrook, ME

    Background/Purpose: The prevalence of hand osteoarthritis (OA) has doubled in the United States over the past half century – a finding that cannot be solely…
  • Abstract Number: 2679 • ACR Convergence 2025

    Early-Life Nutrition and Gene-Environment Interactions Influencing Juvenile Idiopathic Arthritis Risk: Results from a Pregnancy Cohort

    Vilde Øverlien Dåstøl1, Ida Henriette Caspersen2, Kristine Løkås Haftorn3, Sigrid Hestetun4, Siri Eldevik Håberg5, Karen H. Costenbader6, Marin Strøm7, Sjurdur Frodi Olsen8, Anne Lise Brantsæter9, Ketil Størdal10 and Helga Sanner1, 1Oslo University Hospital, Oslo, Norway, 2Norwegian Institute of Public Health, Centre for Fertility and Health/Oslo University Hospital, Oslo, Norway, 3Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 4Oslo University Hospital, Department of Rheumatology/University of Oslo, Oslo, Norway, 5Norwegian Institute of Public Health, Centre for Fertility and Health/University of Bergen, Oslo, Norway, 6Harvard Medical School and Brigham and Women's Hospital, Boston, MA, 7Statens Serum Institut, Department of Epidemiology Research, Copenhagen, Denmark, 8Statens Serum Institut,Biobank, congenital disorders, and vaccines preparedness/Harvard T.H. Chan School of Public Health, Copenhagen, Denmark, 9Norwegian Institute of Public Health, Department of Food Safety and Centre for Sustainable Diets, Oslo, Norway, 10Oslo University Hospital, Department of Pediatric and Adolescent Medicine/University of Oslo, Oslo, Norway

    Background/Purpose: Early-life nutrition may influence the risk of immune-mediated diseases like juvenile idiopathic arthritis (JIA). The benefits of breastfeeding are well established, but findings related…
  • Abstract Number: 2270 • ACR Convergence 2025

    ACKR1 and Leukopenia in Patients with Rheumatoid Arthritis Treated with Disease Modifying Antirheumatic Drugs

    Daniela Chavez de Paz Solis1, Puran Nepa2, Laura Daniel3, Yan Guo4, Jonathan Mosley5, Michael Stein6 and Cecilia Chung4, 1University of Maine, Caribou, ME, 2University of Miami, Research Service, Miami VA Healthcare System, Miami, FL, 3University of Miami, Nashville, TN, 4University of Miami, Miami, 5UT Southwestern Medical Center, Dallas, 6Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, sulfasalazine, and leflunomide arecommonly prescribed for RA treatment but carry the risk of leukopenia. The ACKR1 promoter…
  • Abstract Number: 1909 • ACR Convergence 2025

    Trends of venous thromboembolism after total joint replacement in the United Kingdom after the introduction of NICE guidelines.

    Subhashisa Swain1, Nadja Leith2, Sarah Brown2, Cynthia Wright Drakesmith2, Jonathan Rees3, Clare Bankhead4 and John Powell4, 1Keele University, University of Oxford, Keele, United Kingdom, 2University of Oxford, Oxford, United Kingdom, 3NDORMS, University of Oxford, Oxford, United Kingdom, 4NDPCHS, University of Oxford, Oxford, United Kingdom

    Background/Purpose: Joint replacement (JR) surgery is one of the preferred management for end-stage arthritis. Venous Thromboembolism (VTE) is one of the major post-surgical complications after…
  • Abstract Number: 1883 • ACR Convergence 2025

    Temporal Patterns of Cardiometabolic Comorbidities Before and After Psoriatic Arthritis Diagnosis: A Nationwide Retrospective Study from Poland.

    Batko Bogdan1, Mateusz Szeląg2, Krzysztof Batko3, Magdalena Krajewska-Włodarczyk4, Zbigniew Żuber5, Marcin Stajszczyk6, Brygida Kwiatkowska7 and Tomasz Guzik8, 1Department of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Krakow, Poland, Kraków, Poland, 2Ministry of Health, Warsaw, Poland, 3Department of Dermatology, University Hospital in Krakow, Poland, Krakow, Poland, 4University of Warmia & Mazury, Olsztyn, Poland, 5Department of Pediatrics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Krakow, Poland, Krakow, Poland, 6Department of Rheumatology and Autoimmune Diseases, Silesian Center for Rheumatology, Orthopedics and Rehabilitation, Ustroń, Poland, Ustron, Poland, 7Clinic of Early Arthritis, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, Warsaw, Poland, 8BHF Centre for Research Excellence, Centre for Cardiovascular Sciences, The University of Edin-burgh, Edinburgh, UK, Edinburgh, United Kingdom

    Background/Purpose: While the association between psoriatic arthritis (PsA) and cardiometabolic disorders is established, the temporal sequence and progression of these comorbidities remain poorly characterized. To…
  • Abstract Number: 1500 • ACR Convergence 2025

    Prognostic Impact of Thrombocytopenia on Morbidity and Mortality in Systemic Lupus Erythematosus: A Retrospective Single-Center Study

    Milad Heydari-Kamjani1, Amir Daneshvar2, Dana Nachawati2, Elleson Harper2, Keri Ann Pfeil2, Meghan Gump2, Lindsay Frumker3 and Omer Pamuk1, 1University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, 2University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, 3University hospitals Cleveland medical center, Highland Heights, OH

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with heterogeneous hematologic manifestations. Thrombocytopenia (TP) in SLE may be associated with major organ involvement…
  • Abstract Number: 1247 • ACR Convergence 2025

    Relation of Measures of Pain Sensitization to Widespread Pain

    ZHIQIANG WANG1, Sarah Tilley2, Laura Frey Law3, Cora Lewis4, Michael Nevitt5, Kosaku Aoyagi6, Chunyi Wen7, Changhai Ding1 and Tuhina Neogi8, 1Zhujiang Hospital, Southern Medical University, Guangzhou, China (People's Republic), 2Boston University School of Medicine, Somerville, MA, 3Department of Physical Therapy and Rehabilitation Science, Carver College of Medicine, University of Iowa, Iowa City, IA, 4The University of Alabama at Birmingham, Birmingham, AL, 5University of California, San Francisco, San Francisco, CA, 6University of Texas at El Paso, El Paso, TX, 7The Hong Kong Polytechnic University, Hong Kong, China (People's Republic), 8Boston University School of Medicine, Boston, MA

    Background/Purpose: Widespread pain (WSP) is thought to be related to alterations in nociceptive signaling such as pain sensitization. Whether pain sensitization predisposes to an increase…
  • 1
  • 2
  • 3
  • …
  • 55
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology